A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Seattle Children's Hospital
Universitätsklinikum Hamburg-Eppendorf
Milton S. Hershey Medical Center
Institut Curie
The Hospital for Sick Children
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
The University of Texas Health Science Center, Houston